Researchers at Mayo Clinic have identified a rare mutation in the MET gene that directly causes metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease. The groundbreaking discovery, published on March 7, 2026, in the journal Hepatology, marks the first time a specific genetic mutation has been pinpointed as a direct cause of this widespread condition, which affects more than 100 million Americans. The finding emerged from Mayo Clinic's large-scale Tapestry study involving over 100,000 participants and could fundamentally reshape how doctors screen for and treat the disease.
The research was led by Dr. Filippo Pinto e Vairo, Medical Director of the Program for Rare and Undiagnosed Diseases at Mayo Clinic, alongside Dr. Konstantinos N. Lazaridis, Executive Director of Mayo Clinic's Center for Individualized Medicine, and Dr. Raul Urrutia from the Medical College of Wisconsin. The breakthrough began when the team studied a woman and her father who both suffered from severe fatty liver disease despite lacking the typical risk factors. Neither patient had diabetes nor abnormal cholesterol levels, prompting researchers to investigate a possible genetic explanation.
The MET gene plays a critical role in regulating liver repair and fat metabolism. When the gene carries the identified mutation, fat accumulates in liver cells, triggering a cascade of inflammation that can progress to fibrosis, scarring, and ultimately cirrhosis or liver cancer. Among approximately 4,000 adults diagnosed with MASLD in the Tapestry study, roughly one percent carried rare and potentially causative MET gene variants. Of those carriers, about 18 percent had variants located in the same critical region of the gene as the mutation found in the initial family studied by the team.
Dr. Lazaridis stated that the finding has the potential to affect hundreds of thousands of people worldwide. The discovery challenges the traditional medical understanding that fatty liver disease results exclusively from lifestyle factors such as poor diet, lack of exercise, and obesity. By establishing a clear genetic pathway, the research opens the door to genetic screening that could identify individuals at heightened risk before symptoms appear, allowing for earlier intervention and monitoring.
The implications for treatment are equally significant. With a specific genetic target now identified, pharmaceutical researchers can begin developing therapies that address the root molecular cause of the disease rather than simply managing symptoms. Targeted treatments aimed at correcting or compensating for the MET gene dysfunction could offer a new frontier in combating liver disease, which remains one of the leading causes of death globally.
Fatty liver disease has long been associated primarily with metabolic syndrome and sedentary lifestyles, and its prevalence has surged in recent decades alongside rising obesity rates. The Mayo Clinic discovery suggests that a meaningful subset of patients may carry genetic predispositions that make them vulnerable regardless of their lifestyle choices. This realization could reduce stigma around the diagnosis and encourage more comprehensive genetic testing as part of routine liver disease evaluation.
The study represents a major step forward in the field of individualized medicine. As genetic sequencing becomes more accessible and affordable, the identification of the MET gene mutation as a driver of fatty liver disease could lead to population-level screening programs. Researchers emphasized that further studies are needed to fully understand the range of MET gene variants involved and to develop clinical guidelines for genetic testing and targeted intervention strategies.
Comments